Cross-Sector entity
Terns Pharmaceuticals is most often covered alongside Keytruda, which appears in 7 of these 11 stories. That works out to roughly 0.5 stories per week across a 151-day span. The busiest single day carried 7. The clearest coverage concentration is acquisition: 5 of 11 stories, with the rest divided among 4 other categories.
11 verified stories tracked
Last mentioned: 2d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Terns Pharmaceuticals is most often covered alongside Keytruda, which appears in 7 of these 11 stories. That works out to roughly 0.5 stories per week across a 151-day span. The busiest single day carried 7. The clearest coverage concentration is acquisition: 5 of 11 stories, with the rest divided among 4 other categories. 0% of these stories carry negative sentiment. Terns Pharmaceuticals appears in 11 tracked Cross-Sector stories published from March 25, 2026 through August 22, 2026. The tracked stories average 2 original sources each.
Computed from the 11 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Terns Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Argus raises Merck price target
Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
Merck discloses Evaxion stake
Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Merck exercises EVX-B3 option
Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck's disclosure of a 1.21 million-share stake in Evaxion A/S signals growing pharma confidence in AI-discovered vaccine candidates. For health systems, the partnership could accelerate a new class of antigen-targeted vaccines for bacterial pathogens.
Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Merck's stake in Evaxion is a small but meaningful validation that AI can identify viable vaccine antigens. For AI researchers, the EVX-B3 license signals pharma interest in computational biology beyond diagnostics.
Source: insidermonkey.com · finance.yahoo.com
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Source: abcnews.com · clickorlando.com
